ILLUMINA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.8 USD | -3.42% |
|
-1.90% | -13.85% |
| 05:51pm | Bernstein Adjusts Illumina's Price Target to $130 From $129 | MT |
| 05:50pm | TD Cowen Adjusts Illumina's Price Target to $140 From $150 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
124
USD
Average target price
155.4
USD
Spread / Average Target
+25.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.85% | 19.75B | |
| +8.29% | 218B | |
| +7.46% | 183B | |
| +13.36% | 134B | |
| +26.16% | 106B | |
| -1.33% | 61.12B | |
| +4.81% | 50.89B | |
| +0.45% | 40.3B | |
| +2.82% | 35.53B | |
| +26.33% | 32.05B |
- Stock Market
- Equities
- ILMN Stock
- News Illumina, Inc.
- Illumina : Canaccord Genuity Upgrades Illumina to Buy From Hold; Price Target is $445
